Safety and efficacy of single vs. dual antiplatelet therapy (DAPT) in patients undergoing TAVI remain to be addressed.
Which is the best anti-aggregant or anti-coagulant therapy after TAVI? A propensity matched analysis from the ITER registry. The management of DAPT after TAVI
COLOMBO, ANTONIO;
2017-01-01
Abstract
Safety and efficacy of single vs. dual antiplatelet therapy (DAPT) in patients undergoing TAVI remain to be addressed.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
